Guidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 25, 2023
July 25, 2023
90470c75-0c9c-4b55-a4dd-bb7a0d572e79
Related Documents
Questions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk: Guidance for Industry
Guidance DocumentJuly 25, 2023Center for Drug Evaluation and Research
M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES: Guidance for Industry
Guidance DocumentJuly 25, 2023Center for Drug Evaluation and Research
Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals
Guidance DocumentJune 5, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox